Adial Pharmaceuticals Aktie - ADIL

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

0,702

Gebot

0,682

Fragen

0,7509

Volumen

54.493

0,71 Tagesbereich 0,7515

0,70 52-Wochen-Bereich 3,10

Marktkapitalisierung

4,497M

Handelsende

0,7499

Handelsbeginn

0,73

Letzte Trade

0.72

Letzter Handelszeitpunkt

Finanzvolumen

US$ 39.386

VWAP

0,722777

Durchschnittliches Volumen (3 Mio.)

902.763

Ausgegebene Aktien

6.405.781

Dividendenrendite

Kurs-Gewinn-Verhältnis

-0,90

Gewinn pro Aktie (EPS)

-0,8

Erlöse

Nettogewinn

-5,12M

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.adialpharma.com

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Adial Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ADIL. The last closing price for Adial Pharmaceuticals was US$0,75. Over the last year, Adial Pharmaceuticals shares have traded in a share price range of US$ 0,70 to US$ 3,10.

Adial Pharmaceuticals currently has 6.405.781 shares in issue. The market capitalisation of Adial Pharmaceuticals is US$4,80 million. Adial Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.90.

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or...

Form 8-K - Current report

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

FDA feedback confirms Adial’s proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the...

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or...

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

GLEN ALLEN, Va., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the...

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and...

Form 8-K - Current report

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.046	-6.14973262032	0.748	0.7942	0.7	75013	0.74629482	CS
4	-0.098	-12.25	0.8	1.3	0.7	2345122	0.91489843	CS
12	-0.398	-36.1818181818	1.1	1.3	0.7	902763	0.9173146	CS
26	-0.308	-30.495049505	1.01	1.3	0.7	492782	0.9486963	CS
52	-1.328	-65.4187192118	2.03	3.1	0.7	1585977	1.68642197	CS
156	-45.048	-98.4655737705	45.75	56.625	0.7	1218641	5.26082303	CS
260	-32.798	-97.9044776119	33.5	127	0.7	1049497	23.26996654	CS

ADIL - Frequently Asked Questions (FAQ)

What is the current Adial Pharmaceuticals share price?

The current share price of Adial Pharmaceuticals is US$ 0,702

How many Adial Pharmaceuticals shares are in issue?

Adial Pharmaceuticals has 6.405.781 shares in issue

What is the market cap of Adial Pharmaceuticals?

The market capitalisation of Adial Pharmaceuticals is USD 4,8M

What is the 1 year trading range for Adial Pharmaceuticals share price?

Adial Pharmaceuticals has traded in the range of US$ 0,70 to US$ 3,10 during the past year

What is the PE ratio of Adial Pharmaceuticals?

The price to earnings ratio of Adial Pharmaceuticals is -0,9

What is the reporting currency for Adial Pharmaceuticals?

Adial Pharmaceuticals reports financial results in USD

What is the latest annual profit for Adial Pharmaceuticals?

The latest annual profit of Adial Pharmaceuticals is USD -5,12M

What is the registered address of Adial Pharmaceuticals?

The registered address for Adial Pharmaceuticals is CORPORATION TRUST CENTER 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Adial Pharmaceuticals website address?

The website address for Adial Pharmaceuticals is www.adialpharma.com

Which industry sector does Adial Pharmaceuticals operate in?

Adial Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
CAPSCapstone Holding Corp	US$ 3,11 (1.144,00%)	74,5k
HMRHeidmar Maritime Holdings Corporation	US$ 2,5599 (69,53%)	37,58M
RDFNRedfin Corporation	US$ 9,76 (67,70%)	92,54M
CKPTCheckpoint Therapeutics Inc	US$ 3,9895 (61,52%)	60,92M
STSSSharps Technology Inc	US$ 0,4399 (48,26%)	591,61M
SXTCChina SXT Pharmaceuticals Inc	US$ 2,78 (-35,54%)	162,75k
PCLAPicoCELA Inc	US$ 0,8499 (-35,12%)	866,61k
CONLGraniteShares ETF Trust GraniteShares	US$ 15,685 (-34,86%)	8,71M
MSTXTidal Trust II Defiance Daily Target 2x Long MSTR ETF	US$ 19,22 (-32,95%)	24,19M
JVACoffee Holdings Co	US$ 6,53 (-31,77%)	988,94k
STSSSharps Technology Inc	US$ 0,4399 (48,26%)	591,61M
NVDANVIDIA Corporation	US$ 106,98 (-5,07%)	364,12M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 7,3701 (-30,86%)	258,67M
TSLATesla Inc	US$ 222,15 (-15,43%)	188,57M
TQQQProShares UltraPro QQQ	US$ 59,81 (-11,27%)	155,18M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Adial Pharmaceuticals Inc (ADIL)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Adial Pharmaceuticals Inc

ADIL Neueste Nachrichten

Form 8-K - Current report

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Form 8-K - Current report

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Form 8-K - Current report

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

ADIL - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Adial Pharmaceuticals Inc (ADIL) Börsenkurse

Adial Pharmaceuticals Inc (ADIL)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Adial Pharmaceuticals Inc

ADIL Neueste Nachrichten

Form 8-K - Current report

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Form 8-K - Current report

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Form 8-K - Current report

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

ADIL - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen